Join us for an engaging conversation between Julian Minett, CEO of Spencer Group, and François Torche, Chief Product & Technology Officer & Co-Founder at CluePoints, as they delve into the transformative potential of AI in clinical trials and the pharmaceutical technology marketplace.
While renowned as a world-leading player in Risk-Based Quality Management (RBQM), CluePoints has quietly been developing a sophisticated machine learning application, positioning them with a significant edge in the AI landscape within PharmaTech.
Together, Julian and François unravel the profound implications of AI within corporate environments, exploring its strategic applications and implications for businesses across the sector. Gain exclusive insights into the synergy between AI and cutting-edge clinical trial methodologies that are reshaping the future of pharmaceutical technology.
For more information about CluePoints and their groundbreaking work, please visit www.cluepoints.com.
Listen to the podcast below:
